The results of the phase II IMvigor 210 study demonstrated sthat previously-untreated patients taking Tecentriq lived an average of nearly 15 months. Of those people who responded, 75%
Orphan Drug Designation by the FDA provides regulatory and financial incentives to develop therapies for life-threatening or chronically debilitating conditions affecting fewer than 200 000 people in the
The Bioreactor 3PACK configuration consists of three 2,000L single-use production bioreactors and associated seed train for scale up, allowing for flexible production with scales from 2,000L to 6,000L
These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aß), which are widely believed to play
Under the agreement, MedImmune and Genisphere will develop novel nanoparticles utilizing its 3DNA dendrimer scaffold with up to six MedImmune oncology molecules, as the nanoparticle configuration may help
The Android-exclusive app, available from the Google Play Store, was developed by Alzheimer’s Research UK and virtual reality specialists VISYON, and uses the widely-available Google Cardboard headset to
The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in
The study will explore if novel CIIE-identified targets, when formulated in the DepoVax delivery system, provide immunogenic responses against parasites that cause life-threatening malaria. The collaborators expect to
ARIAD transferred all rights to its EU operations to Incyte, which has acquired all shares of ARIAD Pharmaceuticals (Luxembourg) S.a.r.l., the parent company of ARIAD’s European subsidiaries responsible
The guidance is expected to take 3-4 months pending the response from the MHRA in the UK. Under a European system called the "Decentralized Procedure" (DCP), a company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.